(Tech Times) – Pfizer’s breast cancer drug Ibrance shows favorable clinical trial after facing delays due to efficacy issues. Ibrance is also well-known as palbociclib and it is currently undergoing phase three study, which is called PALOMA-3 trial. The clinical trials have shown significant improvements in Progression-Free Survival, or PFS. “The results of this trial […]